Molecular profiling of DLBCL patients treated in the PETAL trial
|Study ID||Alternative Stable ID||Type|
Using whole-exome sequencing and shallow whole genome sequencing for simultaneous screening of mutations, copy number alterations, and translocations, 5 biology-based risk profiles could be reproduced in an independent cohort of DLBCL patients, from the PETAL trial.
Study Datasets 1 dataset.
Click on a Dataset ID in the table below to learn more, and to find out who to contact about access to these data
Shallow whole genome sequencing and targeted sequencing of DLBCL patients treated in the PETAL trial
|Illumina HiSeq 4000,Illumina NovaSeq 6000||216|